Development of an LC-MS/MS method for simultaneous determination of ticagrelor and its active metabolite during concomitant treatment with atorvastatin

D Danielak, P Gorzycka, Ł Kruszyna… - … of Chromatography B, 2019 - Elsevier
A combination of antiplatelet drugs with high-intensity statin therapy is a standard in patients
with coronary events. Concomitant treatment with ticagrelor, a moderate CYP3A4 inhibitor …
被引用次数：17 相关文章

Development of an LC-MS/MS method for simultaneous determination of ticagrelor and its active metabolite during concomitant treatment with atorvastatin.

D Danielak, P Gorzycka, Ł Kruszyna… - … of chromatography. B …, 2018 - europepmc.org
A combination of antiplatelet drugs with high-intensity statin therapy is a standard in patients
with coronary events. Concomitant treatment with ticagrelor, a moderate CYP3A4 inhibitor …

Development of an LC-MS/MS method for simultaneous determination of ticagrelor and its active metabolite during concomitant treatment with atorvastatin

D Danielak, P Gorzycka, Ł Kruszyna… - … technologies in the …, 2019 - pubmed.ncbi.nlm.nih.gov
A combination of antiplatelet drugs with high-intensity statin therapy is a standard in patients
with coronary events. Concomitant treatment with ticagrelor, a moderate CYP3A4 inhibitor …

[引用][C] Development of an LC-MS/MS method for simultaneous determination of ticagrelor and its active metabolite during concomitant treatment with atorvastatin

D Danielak, P Gorzycka, Ł Kruszyna… - 2019